Effector Therapeutics Stock Net Asset
| EFTR Stock | USD 0.0002 0.0004 66.67% |
Fundamental analysis of Effector Therapeutics allows traders to better anticipate movements in Effector Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Effector | Net Asset | Build AI portfolio with Effector Stock |
Effector Therapeutics Company Net Asset Analysis
Effector Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Effector Therapeutics Net Asset | 20.54 M |
Most of Effector Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Effector Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Effector Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Effector Therapeutics is extremely important. It helps to project a fair market value of Effector Stock properly, considering its historical fundamentals such as Net Asset. Since Effector Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Effector Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Effector Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Effector Total Assets
Total Assets |
|
Based on the recorded statements, Effector Therapeutics has a Net Asset of 20.54 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Effector Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Effector Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Effector Therapeutics could also be used in its relative valuation, which is a method of valuing Effector Therapeutics by comparing valuation metrics of similar companies.Effector Therapeutics is currently under evaluation in net asset category among its peers.
Effector Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Effector Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Effector Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Effector Therapeutics' value.| Shares | Proathlete Wealth Management Llc | 2025-06-30 | 12.0 |
Effector Fundamentals
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (5.13 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 0.22 % | ||||
| Number Of Shares Shorted | 91.62 K | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 69.65 X | ||||
| Gross Profit | (21.62 M) | ||||
| EBITDA | (32.78 M) | ||||
| Net Income | (35.81 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 20.55 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | (12.57) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 940 | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
| Working Capital | (5.96 M) | ||||
| Net Asset | 20.54 M |
About Effector Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Effector Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Effector Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Effector Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Effector Stock Analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.